Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.
de Fontbrune
Flore Sicre
FS
Hematologie-Greffe, Université Paris 7, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
Robin
Marie
M
Porcher
Raphael
R
Scieux
Catherine
C
de Latour
Régis Peffault
RP
Ferry
Christèle
C
Rocha
Vanderson
V
Boudjedir
Karim
K
Devergie
Agnès
A
Bergeron
Anne
A
Gluckman
Eliane
E
Azoulay
Elie
E
Lapalu
Jordane
J
Socié
Gérard
G
Ribaud
Patricia
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006402:Hematologic Diseases / Q000150:complications*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D000069455:Palivizumab; D011014:Pneumonia / Q000188:drug therapy / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000821:virology; D012189:Retrospective Studies; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab